All sponsors

Guangdong Hengrui Pharmaceutical Co., Ltd

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS25
PHASE 3 / 2-37
RECRUITING15
READOUTS ≤12 MONTHS13
READOUT SLIPPED >6 MO25%

Delay Index: of 12 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Guangdong Hengrui Pharmaceutical Co., Ltd on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
SHR4597
NCT06940700
P2Not yet recruitingAsthma602025-10
SHR-1139 Injection
NCT06875934
P2Active, not recruitingModerate to Severe Plaque Psoriasis1452025-11
SHR-3045 Injection
NCT07233655
P2Active, not recruitingModerate to Severe Active Rheumatoid Arthritis302026-04-21 (-2 mo)
SHR-1905 Injection
NCT07211542
P2RecruitingModerate-to-severe Atopic Dermatitis752026-09 (+5 mo)
HRS-9821 Inhalation Suspension
NCT07640451
P2RecruitingCOPD902026-10
SHR-1819 Injection
NCT07688772
P3Active, not recruitingSeasonal Allergic Rhinitis2202026-12
The SHR-1139 injection
NCT07719530
P2RecruitingPsoriasis602026-12-31
SHR-2173 injection
NCT07354932
P2RecruitingPrimary IgA Nephropathy842027-04
SHR-1819 Injection
NCT07321951
P2Active, not recruitingModerate-to-severe Atopic Dermatitis2012027-06
SHR-2173 Injection
NCT07229742
P2RecruitingActive Lupus Nephritis512027-06
SHR-1139 Injection
NCT07444684
P2Not yet recruitingPyoderma Gangrenosum202027-06
SHR-1139
NCT07758075
P2Not yet recruitingPlaque Psoriasis502027-07
SHR-1139 intravenous injection.
NCT07232576
P2Active, not recruitingAdult Patients With Moderately to Severely Active Ulcerative Colitis212027-08
SHR-2173 injection
NCT07289763
P2RecruitingPrimary Membranous Nephropathy752027-08
SHR-2173 injection
NCT07622342
P2RecruitingGeneralized Myasthenia Gravis602027-09
HR-1703
NCT06653322
P3Active, not recruitingAsthma With Eosinophilic Phenotype4012027-09
SHR-1139 Injection
NCT07923851
P2Not yet recruitingPalmoplantar Pustulosis of Adults402027-11
SHR-1819 Injection
NCT07309055
P3RecruitingAdolescents With Moderate-to-severe Atopic Dermatitis2012027-11
SHR-1905 Injection
NCT07098403
P3RecruitingAsthma4082028-01
SHR-2173 Injection
NCT07299422
P2RecruitingSystemic Lupus Erythematosus2482028-03
SHR-1905 Injection
NCT07132827
P3RecruitingChronic Rhinosinusitis With Nasal Polyps2802028-04
HRS-9813 capsules
NCT07192939
P2RecruitingIPF and PPF2702028-06
SHR-1703 Injection
NCT06441812
P2RecruitingEosinophilic Asthma Patients2002028-09 (+9 mo)
SHR-1819 Injection
NCT06554509
P2/3RecruitingPrurigo Nodularis4232028-10 (+27 mo)
SHR-1703
NCT05979051
P2/3RecruitingEosinophilic Granulomatosis With Polyangiitis1662028-12 (+32 mo)